Akashi Therapeutics Receives Collective Funding Of $1.5 Million To Support HT-100 Clinical Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akashi Therapeutics, Inc. announced today that the Muscular Dystrophy Association (MDA) has made an investment through the MDA Venture Philanthropy program to help fund clinical development of HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. The investment from MDA is part of collective funding totaling $1.5 million that Akashi has received in its most recent fundraising round from MDA and 15 other non-profit organizations to support clinical development of HT-100. The current funding is in addition to more than $1 million in non-profit support from an earlier fundraising round, for a cumulative total of more than $2.5 million raised by Akashi from 25 patient advocacy organizations.

Help employers find you! Check out all the jobs and post your resume.